

# Dana P Goldman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1676320/publications.pdf>

Version: 2024-02-01

291  
papers

13,593  
citations

30070

54  
h-index

29157

104  
g-index

308  
all docs

308  
docs citations

308  
times ranked

13787  
citing authors

#	ARTICLE	IF	CITATIONS
1	Participation of Patients 65 Years of Age or Older in Cancer Clinical Trials. <i>Journal of Clinical Oncology</i> , 2003, 21, 1383-1389.	1.6	936
2	Prescription Drug Cost Sharing. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 61.	7.4	741
3	Variations in the Care of HIV-Infected Adults in the United States. <i>JAMA - Journal of the American Medical Association</i> , 1999, 281, 2305.	7.4	669
4	Differences In Life Expectancy Due To Race And Educational Differences Are Widening, And Many May Not Catch Up. <i>Health Affairs</i> , 2012, 31, 1803-1813.	5.2	522
5	The Care of HIV-Infected Adults in the United States. <i>New England Journal of Medicine</i> , 1998, 339, 1897-1904.	27.0	503
6	Pharmacy Benefits and the Use of Drugs by the Chronically Ill. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 2344.	7.4	433
7	Can patient self-management help explain the SES health gradient?. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 10929-10934.	7.1	419
8	Heterogeneity in Healthy Aging. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2014, 69, 640-649.	3.6	327
9	Expenditures for the Care of HIV-Infected Patients in the Era of Highly Active Antiretroviral Therapy. <i>New England Journal of Medicine</i> , 2001, 344, 817-823.	27.0	274
10	Substantial Health And Economic Returns From Delayed Aging May Warrant A New Focus For Medical Research. <i>Health Affairs</i> , 2013, 32, 1698-1705.	5.2	235
11	Insulin Access and Affordability Working Group: Conclusions and Recommendations. <i>Diabetes Care</i> , 2018, 41, 1299-1311.	8.6	210
12	Are The Young Becoming More Disabled?. <i>Health Affairs</i> , 2004, 23, 168-176.	5.2	206
13	Employer Drug Benefit Plans and Spending on Prescription Drugs. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 1733.	7.4	168
14	Political polarization in US residentsâ€™ COVID-19 risk perceptions, policy preferences, and protective behaviors. <i>Journal of Risk and Uncertainty</i> , 2020, 61, 177-194.	1.5	164
15	Estimating probit models with self-selected treatments. <i>Statistics in Medicine</i> , 2006, 25, 389-413.	1.6	162
16	Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. HCSUS Consortium. HIV Cost and Services Utilization Study. <i>Health Services Research</i> , 2000, 35, 389-416.	2.0	162
17	Association between plasma GFAP concentrations and MRI abnormalities in patients with CT-negative traumatic brain injury in the TRACK-TBI cohort: a prospective multicentre study. <i>Lancet Neurology</i> , The, 2019, 18, 953-961.	10.2	150
18	Aging in America in the Twenty-first Century: Demographic Forecasts from the MacArthur Foundation Research Network on an Aging Society. <i>Milbank Quarterly</i> , 2009, 87, 842-862.	4.4	147

#	ARTICLE	IF	CITATIONS
19	Consequences Of Health Trends And Medical Innovation For The Future Elderly. Health Affairs, 2005, 24, W5-R5-W5-R17.	5.2	126
20	HIV Breakthroughs and Risky Sexual Behavior*. Quarterly Journal of Economics, 2006, 121, 1063-1102.	8.6	126
21	The Health And Cost Consequences Of Obesity Among The Future Elderly. Health Affairs, 2005, 24, W5-R30-W5-R41.	5.2	124
22	Patient Cost-Sharing and Healthcare Spending Growth. Journal of Economic Perspectives, 2011, 25, 47-68.	5.9	119
23	Assessment of Follow-up Care After Emergency Department Presentation for Mild Traumatic Brain Injury and Concussion. JAMA Network Open, 2018, 1, e180210.	5.9	119
24	Legal Status And Health Insurance Among Immigrants. Health Affairs, 2005, 24, 1640-1653.	5.2	117
25	Opioid prescribing by multiple providers in Medicare: retrospective observational study of insurance claims. BMJ, The, 2014, 348, g1393-g1393.	6.0	116
26	Estimated prevalence of undiagnosed atrial fibrillation in the United States. PLoS ONE, 2018, 13, e0195088.	2.5	116
27	Impact of oral nutritional supplementation on hospital outcomes. American Journal of Managed Care, 2013, 19, 121-8.	1.1	115
28	Effect of Insurance on Mortality in an HIV-Positive Population in Care. Journal of the American Statistical Association, 2001, 96, 883-894.	3.1	113
29	The increasing value of education to health. Social Science and Medicine, 2011, 72, 1728-1737.	3.8	110
30	Immigrants And The Cost Of Medical Care. Health Affairs, 2006, 25, 1700-1711.	5.2	109
31	Benefit Design And Specialty Drug Use. Health Affairs, 2006, 25, 1319-1331.	5.2	109
32	The link between public and private insurance and HIV-related mortality. Journal of Health Economics, 2003, 22, 1105-1122.	2.7	103
33	Functional Outcomes Over the First Year After Moderate to Severe Traumatic Brain Injury in the Prospective, Longitudinal TRACK-TBI Study. JAMA Neurology, 2021, 78, 982.	9.0	103
34	Out-of-Pocket Medication Costs and Use of Medications and Health Care Services Among Children With Asthma. JAMA - Journal of the American Medical Association, 2012, 307, 1284.	7.4	96
35	Forecasting the Nursing Home Population. Medical Care, 2003, 41, 8-20.	2.4	95
36	Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. American Journal of Managed Care, 2006, 12, 21-8.	1.1	90

#	ARTICLE	IF	CITATIONS
37	Hospital Spending and Inpatient Mortality: Evidence From California. <i>Annals of Internal Medicine</i> , 2011, 154, 160.	3.9	81
38	Racial and ethnic disparities in medication adherence among privately insured patients in the United States. <i>PLoS ONE</i> , 2019, 14, e0212117.	2.5	79
39	An economic evaluation of the war on cancer. <i>Journal of Health Economics</i> , 2010, 29, 333-346.	2.7	74
40	Exenatide Therapy and the Risk of Pancreatitis and Pancreatic Cancer in a Privately Insured Population. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, 904-911.	4.4	74
41	Economic Burden of Undiagnosed Nonvalvular Atrial Fibrillation in the United States. <i>American Journal of Cardiology</i> , 2015, 116, 733-739.	1.6	73
42	Aligning incentives to fulfil the promise of personalised medicine. <i>Lancet, The</i> , 2015, 385, 2118-2119.	13.7	72
43	Point-of-Care Platform Blood Biomarker Testing of Glial Fibrillary Acidic Protein versus S100 Calcium-Binding Protein B for Prediction of Traumatic Brain Injuries: A Transforming Research and Clinical Knowledge in Traumatic Brain Injury Study. <i>Journal of Neurotrauma</i> , 2020, 37, 2460-2467.	3.4	72
44	High Out-Of-Pocket Health Care Spending By The Elderly. <i>Health Affairs</i> , 2003, 22, 194-202.	5.2	71
45	Undiagnosed Disease, Especially Diabetes, Casts Doubt On Some Of Reported Health "Advantage" Of Recent Mexican Immigrants. <i>Health Affairs</i> , 2012, 31, 2727-2737.	5.2	71
46	Hospital Prescribing of Opioids to Medicare Beneficiaries. <i>JAMA Internal Medicine</i> , 2016, 176, 990.	5.1	71
47	Incremental Treatment Costs in National Cancer Institute-Sponsored Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2003, 289, 2970.	7.4	70
48	Toward a 21st-Century Health Care System: Recommendations for Health Care Reform. <i>Annals of Internal Medicine</i> , 2009, 150, 493.	3.9	68
49	Does age or life expectancy better predict health care expenditures?. <i>Health Economics (United Tj ETQq1 1 0.784314 rgBT /Qyerlock</i>	1.7	67
50	Sexually Transmitted Diseases Among Users of Erectile Dysfunction Drugs: Analysis of Claims Data. <i>Annals of Internal Medicine</i> , 2010, 153, 1.	3.9	65
51	The Effect Of Regulation On Pharmaceutical Revenues: Experience In Nineteen Countries. <i>Health Affairs</i> , 2008, 27, w125-w137.	5.2	64
52	Incidence of Sexually Transmitted Infections After Human Papillomavirus Vaccination Among Adolescent Females. <i>JAMA Internal Medicine</i> , 2015, 175, 617.	5.1	63
53	The Benefits of Risk Factor Prevention in Americans Aged 51 Years and Older. <i>American Journal of Public Health</i> , 2009, 99, 2096-2101.	2.7	62
54	MEDICAL EXPENDITURE RISK AND HOUSEHOLD PORTFOLIO CHOICE. <i>Journal of Applied Econometrics</i> , 2013, 28, 527-550.	2.3	58

#	ARTICLE	IF	CITATIONS
55	An Analysis Of Whether Higher Health Care Spending In The United States Versus Europe Is "Worth It"™ In The Case Of Cancer. Health Affairs, 2012, 31, 667-675.	5.2	57
56	Mortality and Treatment Patterns Among Patients Hospitalized With Acute Cardiovascular Conditions During Dates of National Cardiology Meetings. JAMA Internal Medicine, 2015, 175, 237.	5.1	56
57	Effective HIV Treatment and the Employment of HIV+ Adults. Health Services Research, 2004, 39, 1691-1712.	2.0	53
58	Integrated Insurance Design in the Presence of Multiple Medical Technologies. American Economic Review, 2007, 97, 427-432.	8.5	53
59	Confounding in the Association of Proton Pump Inhibitor Use With Risk of Community-Acquired Pneumonia. Journal of General Internal Medicine, 2013, 28, 223-230.	2.6	53
60	Early Failure of Dialysis Access among the Elderly in the Era of Fistula First. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1791-1798.	4.5	53
61	The Changing Face Of Pharmacy Benefit Design. Health Affairs, 2004, 23, 194-199.	5.2	52
62	The Lifetime Burden Of Chronic Disease Among The Elderly. Health Affairs, 2005, 24, W5-R18-W5-R29.	5.2	52
63	Managed Care as a Public Cost-Containment Mechanism. RAND Journal of Economics, 1995, 26, 277.	2.3	51
64	The Value of Specialty Oncology Drugs. Health Services Research, 2010, 45, 115-132.	2.0	49
65	The Disability Burden of COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2012, 9, 513-521.	1.6	49
66	Cost Sharing and the Initiation of Drug Therapy for the Chronically Ill. Archives of Internal Medicine, 2009, 169, 740.	3.8	48
67	Cost Sharing, Family Health Care Burden, and the Use of Specialty Drugs for Rheumatoid Arthritis. Health Services Research, 2010, 45, 1227-1250.	2.0	46
68	Preparedness of Americans for the Affordable Care Act. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 5497-5502.	7.1	46
69	Health Status and Medical Treatment of the Future Elderly: Final Report. , 2004, , .		46
70	The Association between Employee Obesity and Employer Costs: Evidence from a Panel of U.S. Employers. American Journal of Health Promotion, 2014, 28, 277-285.	1.7	45
71	The association between observed mobility and quality of life in the near elderly. PLoS ONE, 2017, 12, e0182920.	2.5	44
72	The Large Social Value Resulting From Use Of Statins Warrants Steps To Improve Adherence And Broaden Treatment. Health Affairs, 2012, 31, 2276-2285.	5.2	43

#	ARTICLE	IF	CITATIONS
73	Disability And Health Care Spending Among Medicare Beneficiaries. Health Affairs, 2005, 24, W5-R42-W5-R52.	5.2	41
74	The Emerging Importance of Patient Amenities in Hospital Care. New England Journal of Medicine, 2010, 363, 2185-2187.	27.0	41
75	The costs of developing treatments for Alzheimer's disease: A retrospective exploration. Alzheimer's and Dementia, 2022, 18, 469-477.	0.8	40
76	A Theory of Health Disparities and Medical Technology. BE Journal of Economic Analysis and Policy, 2005, 4, .	0.2	39
77	U.S. Pharmaceutical Policy In A Global Marketplace. Health Affairs, 2008, 27, w138-w150.	5.2	39
78	Differences in health between Americans and Western Europeans: Effects on longevity and public finance. Social Science and Medicine, 2011, 73, 254-263.	3.8	39
79	Health and Health Care of Medicare Beneficiaries in 2030. Forum for Health Economics and Policy, 2015, 18, 75-96.	0.8	39
80	Association Between the Birth of Twins and Parental Divorce. Obstetrics and Gynecology, 2011, 117, 892-897.	2.4	38
81	How the Growing Gap in Life Expectancy May Affect Retirement Benefits and Reforms. Geneva Papers on Risk and Insurance: Issues and Practice, 2017, 42, 475-499.	2.1	37
82	Multidimensional comparison of countries' adaptation to societal aging. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 9169-9174.	7.1	37
83	Measuring The Lifetime Costs Of Serious Mental Illness And The Mitigating Effects Of Educational Attainment. Health Affairs, 2019, 38, 652-659.	5.2	37
84	How Costly is Hospital Quality? A Revealed-Preference Approach. Journal of Industrial Economics, 2011, 59, 578-608.	1.3	36
85	Nearly 60,000 Uninsured And Low-Income People With HIV/AIDS Live In States That Are Not Expanding Medicaid. Health Affairs, 2014, 33, 386-393.	5.2	35
86	Innovation in Heart Failure Treatment. JACC: Heart Failure, 2018, 6, 401-409.	4.1	34
87	Geographic Variation in Health Care: The Role of Private Markets. Brookings Papers on Economic Activity, 2010, 2010, 325-355.	1.5	33
88	Using Self-reports or Claims to Assess Disease Prevalence. Medical Care, 2017, 55, 782-788.	2.4	33
89	Cost-Containment and Adverse Selection in Medicaid HMOs. Journal of the American Statistical Association, 1998, 93, 54-62.	3.1	32
90	Valuing health technologies at nice: recommendations for improved incorporation of treatment value in HTA. Health Economics (United Kingdom), 2010, 19, 1109-1116.	1.7	32

#	ARTICLE	IF	CITATIONS
91	Early HIV Treatment Led To Life Expectancy Gains Valued At \$80ÂBillion For People Infected In 1996â€“2009. Health Affairs, 2014, 33, 370-377.	5.2	32
92	Growing Internet Use May Help Explain The Rise In Prescription Drug Abuse In The United States. Health Affairs, 2011, 30, 1192-1199.	5.2	31
93	Patients Value Metastatic Cancer Therapy More Highly Than Is Typically Shown Through Traditional Estimates. Health Affairs, 2012, 31, 691-699.	5.2	31
94	Economic Value of Antiâ€“Vascular Endothelial Growth Factor Treatment for Patients With Wet Age-Related Macular Degeneration in the United States. JAMA Ophthalmology, 2020, 138, 40.	2.5	31
95	Association between use of warfarin with common sulfonylureas and serious hypoglycemic events: retrospective cohort analysis. BMJ, The, 2015, 351, h6223.	6.0	30
96	Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains, But Capacity Is A Concern. Health Affairs, 2015, 34, 1666-1674.	5.2	30
97	Socioeconomic Differences in the Adoption of New Medical Technologies. American Economic Review, 2005, 95, 234-237.	8.5	29
98	The Benefits From Giving Makers Of Conventional â€“Small Moleculeâ€™ Drugs Longer Exclusivity Over Clinical Trial Data. Health Affairs, 2011, 30, 84-90.	5.2	29
99	Encouraging New Uses for Old Drugs. JAMA - Journal of the American Medical Association, 2017, 318, 2421.	7.4	29
100	Methodological biases in estimating the burden of out-of-pocket expenses. Health Services Research, 2001, 35, 1357-65; discussion 1365-70.	2.0	29
101	The potential impact of comparative effectiveness research on U.S. Health Care expenditures. Demography, 2010, 47, S173-S190.	2.5	28
102	Measuring the Incremental Cost of Clinical Cancer Research. Journal of Clinical Oncology, 2001, 19, 105-110.	1.6	27
103	Racial and ethnic disparities in hospital care resulting from air pollution in excess of federal standards. Social Science and Medicine, 2011, 73, 1163-1168.	3.8	27
104	Medicaid Cost Control Measures Aimed At Second-Generation Antipsychotics Led To Less Use Of All Antipsychotics. Health Affairs, 2011, 30, 2346-2354.	5.2	27
105	HIV Care Providers Emphasize The Importance Of The Ryan White Program For Access To And Quality Of Care. Health Affairs, 2014, 33, 394-400.	5.2	27
106	Pharmacy Benefit Caps And The Chronically Ill. Health Affairs, 2007, 26, 1333-1344.	5.2	26
107	The Growing Gap in Life Expectancy: Using the Future Elderly Model to Estimate Implications for Social Security and Medicare. American Economic Review, 2014, 104, 230-233.	8.5	26
108	The Impact of State Policy on the Costs of HIV Infection. Medical Care Research and Review, 2001, 58, 31-53.	2.1	25

#	ARTICLE	IF	CITATIONS
109	Hospital Costs and Inpatient Mortality among Children Undergoing Surgery for Congenital Heart Disease. <i>Health Services Research</i> , 2014, 49, 588-608.	2.0	25
110	Accelerating Alzheimer's disease drug innovations from the research pipeline to patients. <i>Alzheimer's and Dementia</i> , 2018, 14, 833-836.	0.8	25
111	The long-term impact of functional disability on hospitalization spending in Singapore. <i>Journal of the Economics of Ageing</i> , 2019, 14, 100193.	1.3	25
112	Prescription Medication Abuse and Illegitimate Internet-Based Pharmacies. <i>Annals of Internal Medicine</i> , 2011, 155, 848.	3.9	24
113	The value of medical and pharmaceutical interventions for reducing obesity. <i>Journal of Health Economics</i> , 2012, 31, 630-643.	2.7	24
114	Inhaled corticosteroids and the risk of pneumonia in Medicare patients with COPD. <i>Current Medical Research and Opinion</i> , 2012, 28, 1959-1967.	1.9	23
115	Does Medicare Coverage Improve Cancer Detection and Mortality Outcomes?. <i>Journal of Policy Analysis and Management</i> , 2020, 39, 577-604.	1.4	23
116	Digesting the doughnut hole. <i>Journal of Health Economics</i> , 2013, 32, 1345-1355.	2.7	22
117	HETEROGENEITY IN ACTION: THE ROLE OF <i>PASSIVE</i> PERSONALIZATION IN COMPARATIVE EFFECTIVENESS RESEARCH. <i>Health Economics (United Kingdom)</i> , 2014, 23, 359-373.	1.7	22
118	Early HIV Treatment In The United States Prevented Nearly 13,500 Infections Per Year During 1996â€“2009. <i>Health Affairs</i> , 2014, 33, 362-369.	5.2	22
119	Cancer Mortality Reductions Were Greatest Among Countries Where Cancer Care Spending Rose The Most, 1995â€“2007. <i>Health Affairs</i> , 2015, 34, 562-570.	5.2	22
120	The Impact of the US Food and Drug Administration Chlorofluorocarbon Ban on Out-of-pocket Costs and Use of Albuterol Inhalers Among Individuals With Asthma. <i>JAMA Internal Medicine</i> , 2015, 175, 1171.	5.1	22
121	Health Care Spending: Historical Trends and New Directions. <i>Annual Review of Economics</i> , 2016, 8, 291-319.	5.5	22
122	Projecting diabetes prevalence among Mexicans aged 50 years and older: the Future Elderly Model-Mexico (FEM-Mexico). <i>BMJ Open</i> , 2017, 7, e017330.	1.9	22
123	Spending and mortality in US acute care hospitals. <i>American Journal of Managed Care</i> , 2013, 19, e46-54.	1.1	22
124	Cost-sharing and initiation of disease-modifying therapy for multiple sclerosis. <i>American Journal of Managed Care</i> , 2012, 18, 460-4.	1.1	22
125	Identifying Potential Health Care Innovations For The Future Elderly. <i>Health Affairs</i> , 2005, 24, W5-R67-W5-R76.	5.2	21
126	Specialty Drug Spending Trends Among Medicare And Medicare Advantage Enrollees, 2007â€“11. <i>Health Affairs</i> , 2014, 33, 2018-2024.	5.2	21



#	ARTICLE	IF	CITATIONS
127	Measuring how countries adapt to societal aging. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 435-437.	7.1	21
128	Improving the quality of care through routine teleradiology consultation. Academic Radiology, 2000, 7, 149-155.	2.5	20
129	Disability Forecasts and Future Medicare Costs. Forum for Health Economics and Policy, 2004, 7, 75-94.	0.8	20
130	Technological Advances In Cancer And Future Spending By The Elderly. Health Affairs, 2005, 24, W5-R53-W5-R66.	5.2	20
131	Survey Results Show That Adults Are Willing To Pay Higher Insurance Premiums For Generous Coverage Of Specialty Drugs. Health Affairs, 2012, 31, 683-690.	5.2	20
132	Do Physicians Respond to the Costs and Cost-Sensitivity of Their Patients?. American Economic Journal: Economic Policy, 2018, 10, 113-152.	3.1	20
133	THE FISCAL CONSEQUENCES OF TRENDS IN POPULATION HEALTH. National Tax Journal, 2010, 63, 307-330.	1.2	20
134	Impact of type 2 diabetes medication cost sharing on patient outcomes and health plan costs. American Journal of Managed Care, 2016, 22, 433-40.	1.1	20
135	A Socioeconomic Profile of Older Adults With HIV. Journal of Health Care for the Poor and Underserved, 2005, 16, 19-28.	0.8	19
136	Clinical and Behavioral Correlates of Achieving and Maintaining Glycemic Targets in an Underserved Population With Type 2 Diabetes. Diabetes Care, 2009, 32, 54-56.	8.6	19
137	Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer. JAMA Oncology, 2015, 1, 196.	7.1	19
138	Insurance status of HIV-infected adults in the post-HAART era: evidence from the United States. Applied Health Economics and Health Policy, 2003, 2, 85-90.	2.1	19
139	Formulary restrictions on atypical antipsychotics: impact on costs for patients with schizophrenia and bipolar disorder in Medicaid. American Journal of Managed Care, 2014, 20, e52-60.	1.1	19
140	Medical Expenditure Measures in the Health and Retirement Study. Forum for Health Economics and Policy, 2011, 14, 4.	0.8	18
141	An Economic Analysis of Conservative Management Versus Active Treatment for Men with Localized Prostate Cancer. Journal of the National Cancer Institute Monographs, 2012, 2012, 250-257.	2.1	18
142	The Economic Promise of Delayed Aging. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a025072.	6.2	18
143	Variation in Inpatient Resource Use in the Treatment of HIV. Medical Care, 1999, 37, 220-227.	2.4	18
144	Queuing for Surgery: Is the U.S. or Canada Worse Off?. Review of Economics and Statistics, 2000, 82, 297-308.	4.3	17

#	ARTICLE	IF	CITATIONS
145	The Value of Elderly Disease Prevention. Forum for Health Economics and Policy, 2006, 9, .	0.8	17
146	The Promise Of Health Care Cost Containment. Health Affairs, 2007, 26, 1545-1547.	5.2	17
147	Drug Licenses: A New Model For Pharmaceutical Pricing. Health Affairs, 2008, 27, 122-129.	5.2	17
148	Coverage and Preventive Screening. Health Services Research, 2011, 46, 173-184.	2.0	17
149	Acute Myocardial Infarction Mortality During Dates of National Interventional Cardiology Meetings. Journal of the American Heart Association, 2018, 7, .	3.7	17
150	The effects of benefit design and managed care on health care costs. Journal of Health Economics, 1995, 14, 401-418.	2.7	16
151	Do Statins Reduce the Health and Health Care Costs of Obesity?. Pharmacoeconomics, 2015, 33, 723-734.	3.3	16
152	US Hospitals Experienced Substantial Productivity Growth During 2002â€“11. Health Affairs, 2015, 34, 511-518.	5.2	16
153	Long-Term Health and Economic Value of Improved Mobility among Older Adults in the United States. Value in Health, 2018, 21, 792-798.	0.3	16
154	Short-term budget affordability of hepatitis C treatments for state Medicaid programs. BMC Health Services Research, 2019, 19, 140.	2.2	16
155	Diabetes Management For Low-Income Patients In Los Angeles: Two Strategies Improved Disease Control In The Short Term. Health Affairs, 2012, 31, 168-176.	5.2	15
156	Did Medicare Part D reduce disparities?. American Journal of Managed Care, 2015, 21, 119-28.	1.1	15
157	Creating the Costliest Orphan: The Orphan Drug Act in the Development of Ceredase. International Journal of Technology Assessment in Health Care, 1992, 8, 583-597.	0.5	14
158	Medicare Part D. JAMA - Journal of the American Medical Association, 2008, 299, 1954-5.	7.4	14
159	Robot-Assisted Surgery For Kidney Cancer Increased Access To A Procedure That Can Reduce Mortality And Renal Failure. Health Affairs, 2015, 34, 220-228.	5.2	14
160	Variations in outcomes of hemodialysis vascular access by race/ethnicity in the elderly. Journal of Vascular Surgery, 2017, 65, 783-792.e4.	1.1	14
161	Frequency and Magnitude of Co-payments Exceeding Prescription Drug Costs. JAMA - Journal of the American Medical Association, 2018, 319, 1045.	7.4	14
162	Functional Status Examination versus Glasgow Outcome Scale Extended as Outcome Measures in Traumatic Brain Injuries: How Do They Compare?. Journal of Neurotrauma, 2019, 36, 2423-2429.	3.4	14

#	ARTICLE	IF	CITATIONS
163	Value of improved lipid control in patients at high risk for adverse cardiac events. American Journal of Managed Care, 2016, 22, e199-207.	1.1	14
164	The Value of Diagnostic Testing in Personalized Medicine. Forum for Health Economics and Policy, 2013, 16, S87-S99.	0.8	13
165	The Societal Value of Broader Access to Antiobesity Medications. Obesity, 2020, 28, 429-436.	3.0	13
166	Disentangling moral hazard and adverse selection in private health insurance. Journal of Econometrics, 2021, 222, 141-160.	6.5	13
167	Opioid-related deaths before and after COVID-19 stay-at-home orders in Los Angeles County. Drug and Alcohol Dependence, 2021, 228, 109028.	3.2	13
168	Medication adherence and measures of health plan quality. American Journal of Managed Care, 2015, 21, e379-89.	1.1	13
169	Price Regulation in Secondary Insurance Markets. Journal of Risk and Insurance, 2004, 71, 643-675.	1.6	12
170	The Contributions of Improved Therapy and Earlier Detection to Cancer Survival Gains, 1988-2000. Forum for Health Economics and Policy, 2010, 13, .	0.8	12
171	Food Prices and the Dynamics of Body Weight. , 0, , 65-90.		12
172	Medicare part D after 2 years. American Journal of Managed Care, 2009, 15, 536-44.	1.1	12
173	Impact of specialty drugs on the use of other medical services. American Journal of Managed Care, 2008, 14, 821-8.	1.1	12
174	Bending the curve: effective steps to address long-term healthcare spending growth. American Journal of Managed Care, 2009, 15, 676-80.	1.1	12
175	Increased Medicare Expenditures for Physicians' Services: What are the Causes?. Inquiry (United Tj ETQq1 1 0.784314 rgBT /Overlock 0,9 11		
176	Drug costs and out-of-pocket spending in cancer clinical trials. Contemporary Clinical Trials, 2008, 29, 1-8.	1.8	11
177	Market evidence of misperceived mortality risk. Journal of Economic Behavior and Organization, 2009, 72, 451-462.	2.0	11
178	The Affordable Care Act and Health Insurance Coverage Among People With Diagnosed and Undiagnosed Diabetes: Data From the National Health and Nutrition Examination Survey. Diabetes Care, 2019, 42, e179-e180.	8.6	11
179	Gender differences in countries' adaptation to societal ageing: an international cross-sectional comparison. The Lancet Healthy Longevity, 2021, 2, e460-e469.	4.6	11
180	Physician prescribing behavior and its impact on patient-level outcomes. American Journal of Managed Care, 2011, 17, e462-71.	1.1	11

#	ARTICLE	IF	CITATIONS
181	Employee responses to health insurance premium increases. American Journal of Managed Care, 2004, 10, 41-7.	1.1	11
182	How Much Savings Can We Wring from Medicare?. New England Journal of Medicine, 2011, 365, e29.	27.0	10
183	The Prospect Of A Generation Free Of HIV May Be Within Reach If The Right Policy Decisions Are Made. Health Affairs, 2014, 33, 428-433.	5.2	10
184	Data-Driven Decision-Making Tools To Improve Public Resource Allocation For Care And Prevention Of HIV/AIDS. Health Affairs, 2014, 33, 410-417.	5.2	10
185	Outcomes-Based Pricing as a Tool to Ensure Access to Novel but Expensive Biopharmaceuticals. Annals of Internal Medicine, 2017, 166, 219.	3.9	10
186	Association Between State Medicaid Eligibility Thresholds and Deaths Due to Substance Use Disorders. JAMA Network Open, 2019, 2, e193056.	5.9	10
187	The future of the elderly population health status: Filling a knowledge gap. Health Economics (United Tj ETQq1 1 0,784314 rgBT /Overl 1.7 FO	1.7	10
188	The economics of alternative payment models for pharmaceuticals. European Journal of Health Economics, 2021, 22, 559-569.	2.8	10
189	Criminal Prosecution and Human Immunodeficiency Virus-Related Risky Behavior. Journal of Law and Economics, 2010, 53, 741-782.	1.4	9
190	Lifetime Burden of Adult Congenital Heart Disease in the USA Using a Microsimulation Model. Pediatric Cardiology, 2020, 41, 1515-1525.	1.3	9
191	Tractography-Pathology Correlations in Traumatic Brain Injury: A TRACK-TBI Study. Journal of Neurotrauma, 2021, 38, 1620-1631.	3.4	9
192	Modelling the value of innovative treatments for Alzheimer's disease in the United States. Journal of Medical Economics, 2021, 24, 764-769.	2.1	9
193	Use of unpaid and paid home care services among people with HIV infection in the USA. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2001, 13, 99-121.	1.2	8
194	Delayed Aging Versus Delayed Disease: A New Paradigm for Public Health. The Public Policy and Aging Report, 2013, 23, 16-18.	1.1	8
195	Five Myths About Cancer Care In America. Health Affairs, 2014, 33, 1801-1804.	5.2	8
196	The Value of Progression-Free Survival in Metastatic Breast Cancer: Results From a Survey of Patients and Providers. MDM Policy and Practice, 2019, 4, 238146831985538.	0.9	8
197	Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017. Value in Health, 2019, 22, 1387-1395.	0.3	8
198	Trends in Racial and Ethnic Disparities in Diabetes-Related Complications, 1997-2017. Journal of General Internal Medicine, 2020, 35, 950-951.	2.6	8

#	ARTICLE	IF	CITATIONS
199	Smaller Regional Brain Volumes Predict Posttraumatic Stress Disorder at 3 Months After Mild Traumatic Brain Injury. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2021, 6, 352-359.	1.5	8
200	Looking Ahead to 2030: Survey of Evolving Needs in Pharmacy Education. <i>Pharmacy (Basel, Switzerland)</i> , 2021, 10, 702-710.	1.6	8
201	The Long-Term Benefits of Increased Aspirin Use by At-Risk Americans Aged 50 and Older. <i>PLoS ONE</i> , 2016, 11, e0166103.	2.5	8
202	Complexity Bias in the Prevention of Iatrogenic Injury. <i>Mayo Clinic Proceedings</i> , 2022, 97, 221-224.	3.0	8
203	The potential impact of CAR T-cell treatment delays on society. <i>American Journal of Managed Care</i> , 2019, 25, 379-386.	1.1	8
204	Part D Formulary and Benefit Design as a Risk-Steering Mechanism. <i>American Economic Review</i> , 2011, 101, 382-386.	8.5	7
205	The Relationship between Commercial Health Care Prices and Medicare Spending and Utilization. <i>Health Services Research</i> , 2015, 50, 883-896.	2.0	7
206	Resetting Social Security. <i>Daedalus</i> , 2015, 144, 68-79.	1.8	7
207	PCSK9 Inhibitors Show Value for Patients and the US Health Care System. <i>Value in Health</i> , 2017, 20, 1270-1278.	0.3	7
208	Association Between Spending and Outcomes for Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 323-331.	1.6	7
209	Predicting quantity and quality of life with the Future Elderly Model. <i>Health Economics (United Kingdom)</i> , 2021, 43, 147-174.	1.7	7
210	Effect of COVID-19 vaccine allocation strategies on vaccination refusal: a national survey. <i>Journal of Risk Research</i> , 2022, 25, 1047-1054.	2.6	7
211	Associations of Intensive Lifestyle Intervention in Type 2 Diabetes With Health Care Use, Spending, and Disability. <i>JAMA Network Open</i> , 2020, 3, e2025488.	5.9	7
212	Medicaid prior authorization policies and imprisonment among patients with schizophrenia. <i>American Journal of Managed Care</i> , 2014, 20, 577-86.	1.1	7
213	Managed Care in Dental Markets: Is the Experience of Medicine Relevant?. <i>Journal of Public Health Dentistry</i> , 1999, 59, 24-32.	1.2	6
214	Rising Medicare Costs: Are We In Crisis?. <i>Health Affairs</i> , 2006, 25, W389-W390.	5.2	6
215	Identifying Patients at Risk for High Medical Costs and Good Candidates for Obesity Intervention. <i>American Journal of Health Promotion</i> , 2014, 28, 218-227.	1.7	6
216	Higher Surgeon Procedure Volume is Associated with Improved Hemodialysis Vascular Access Outcomes. <i>American Surgeon</i> , 2019, 85, 1079-1082.	0.8	6

#	ARTICLE	IF	CITATIONS
217	Extended-Release Formulation and Medication Adherence. <i>Journal of General Internal Medicine</i> , 2020, 35, 354-356.	2.6	6
218	Coverage and use of cancer therapies in the treatment of chronic myeloid leukemia. <i>American Journal of Managed Care</i> , 2012, 18, S272-8.	1.1	6
219	The Costs of A Medicare Prescription Drug Benefit. <i>BE Journal of Economic Analysis and Policy</i> , 2002, 2, .	0.3	5
220	Effect of an imaging-based streamlined electronic healthcare process on quality and costs <sup>1</sup> . <i>Academic Radiology</i> , 2004, 11, 13-20.	2.5	5
221	Can patient self-management explain the health gradient? Goldman and Smith (2002) revisited: A response to Maitra. <i>Social Science and Medicine</i> , 2010, 70, 813-815.	3.8	5
222	Competing Risks. <i>American Journal of Preventive Medicine</i> , 2016, 50, S45-S50.	3.0	5
223	Quantifying Gains in the War on Cancer Due to Improved Treatment and Earlier Detection. <i>Forum for Health Economics and Policy</i> , 2016, 19, 141-156.	0.8	5
224	Measuring Sarcopenia Severity in Older Adults and the Value of Effective Interventions. <i>Journal of Nutrition, Health and Aging</i> , 2018, 22, 1253-1258.	3.3	5
225	Spending On Targeted Therapies Reduced Mortality In Patients With Advanced-Stage Breast Cancer. <i>Health Affairs</i> , 2021, 40, 763-771.	5.2	5
226	Medical Expenditure Risk and Household Portfolio Choice. <i>SSRN Electronic Journal</i> , 2007, , .	0.4	4
227	Three Large-Scale Changes To The Medicare Program Could Curb Its Costs But Also Reduce Enrollment. <i>Health Affairs</i> , 2013, 32, 891-899.	5.2	4
228	Patient Outcomes and Cost Effects of Medicaid Formulary Restrictions on Antidepressants. <i>Forum for Health Economics and Policy</i> , 2014, 17, 153-168.	0.8	4
229	Individual & Social Strategies to Mitigate the Risks & Expand Opportunities of an Aging America. <i>Daedalus</i> , 2015, 144, 93-102.	1.8	4
230	The Impact of State AIDS Drug Assistance Policies on Clinical and Economic Outcomes of People With HIV. <i>Medical Care Research and Review</i> , 2016, 73, 329-348.	2.1	4
231	Development of a Group Judgment Process for Forecasts of Health Care Innovations. <i>JAMA Network Open</i> , 2018, 1, e185108.	5.9	4
232	Geographic variation in the delivery of high-value inpatient care. <i>PLoS ONE</i> , 2019, 14, e0213647.	2.5	4
233	Who Pays in Medicare Part D? Giving Plans More Skin in the Game. <i>New England Journal of Medicine</i> , 2019, 381, 2384-2387.	27.0	4
234	Temporal Trends in Mortality after Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Regression Analysis. <i>Structural Heart</i> , 2020, 4, 16-23.	0.6	4

#	ARTICLE	IF	CITATIONS
235	Risk factors and costs associated with 30-day readmissions following alcohol-related hospitalizations in the United States from 2010 to 2015. <i>Alcohol</i> , 2020, 89, 19-25.	1.7	4
236	Moving towards better formulary management. <i>American Journal of Managed Care</i> , 2005, 11, 13-4.	1.1	4
237	Comparative effectiveness research and formulary placement: the case of diabetes. <i>American Journal of Managed Care</i> , 2013, 19, 93-6.	1.1	4
238	Providing Managed Care Options for a Large Population: Evaluating the CHAMPUS Reform Initiative. <i>Military Medicine</i> , 2000, 165, 403-410.	0.8	3
239	Re: Surveys Identify Barriers to Participation in Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2001, 93, 238-239.	6.3	3
240	Adverse Selection in Retiree Prescription Drug Plans. <i>Forum for Health Economics and Policy</i> , 2006, 9, .	0.8	3
241	A Reexamination of the Costs of Medical R&D Regulation. <i>Forum for Health Economics and Policy</i> , 2012, 15, 1-28.	0.8	3
242	Raising the Social Security Entitlement Age. <i>Research on Aging</i> , 2017, 39, 166-189.	1.8	3
243	Tying Reimbursement to Outcomes Is an Ideal Strategy for PCSK9 Inhibitors. <i>JAMA Cardiology</i> , 2017, 2, 1063.	6.1	3
244	Productivity Benefits of Medical Care: Evidence from US-Based Randomized Clinical Trials. <i>Value in Health</i> , 2018, 21, 905-910.	0.3	3
245	Simulating the Fiscal Impact of Anti-Obesity Medications as an Obesity Reduction Strategy. <i>Inquiry (United States)</i> , 2021, 58, 004695802199051.	0.9	3
246	Disparate ageing: The role of education and socioeconomic gradients in future health and disability in an international context. <i>Health Economics (United Kingdom)</i> , 2021, 30, 3-10.	1.7	3
247	Comparing the Quality of Life after Brain Injury-Overall Scale and Satisfaction with Life Scale as Outcome Measures for Traumatic Brain Injury Research. <i>Journal of Neurotrauma</i> , 2021, 38, 3352-3363.	3.4	3
248	Higher Surgeon Procedure Volume Is Associated with Improved Hemodialysis Vascular Access Outcomes. <i>American Surgeon</i> , 2019, 85, 1079-1082.	0.8	3
249	Bending the curve through health reform implementation. <i>American Journal of Managed Care</i> , 2010, 16, 804-12.	1.1	3
250	The long-term social value of granulocyte colony-stimulating factors. <i>American Journal of Managed Care</i> , 2019, 25, 486-493.	1.1	3
251	An Analysis of Unobserved Selection in an Inpatient Diagnostic Cost Group Model. <i>Health Services and Outcomes Research Methodology</i> , 2003, 4, 71-91.	1.8	2
252	Sampling Patients Within and Across Health Care Providers: Multi-Stage Non-Nested Samples in Health Services Research. <i>Health Services and Outcomes Research Methodology</i> , 2003, 4, 151-167.	1.8	2

#	ARTICLE	IF	CITATIONS
253	A Response to the Points by Manton and Williamson. <i>Medical Care</i> , 2003, 41, 28-31.	2.4	2
254	The reallocation of compensation in response to health insurance premium increases. <i>Economics Letters</i> , 2005, 88, 147-151.	1.9	2
255	Prescription Drug Coverage and Medicare Spending among U.S. Elderly. <i>Geneva Papers on Risk and Insurance: Issues and Practice</i> , 2010, 35, 539-567.	2.1	2
256	Clinical evidence inputs to comparative effectiveness research could impact the development of novel treatments. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 203-213.	1.4	2
257	The social value of tisagenlecleucel, a CAR-T cell therapy, for the treatment of relapsed or refractory pediatric acute lymphoblastic leukemia in the United States: What are consequences of treatment delays?. <i>Journal of Clinical Oncology</i> , 2018, 36, 10529-10529.	1.6	2
258	Redistributional consequences of community rating. <i>Health Services Research</i> , 1997, 32, 71-86.	2.0	2
259	Measuring the value of better diabetes management. <i>American Journal of Managed Care</i> , 2013, 19 Spec No. 2, E11.	1.1	2
260	Do strict formularies replicate failure for patients with schizophrenia?. <i>American Journal of Managed Care</i> , 2014, 20, 219-28.	1.1	2
261	Using Hospital Tumor Registries to Identify Research Subjects. <i>Health Services and Outcomes Research Methodology</i> , 2001, 2, 67-76.	1.8	1
262	Intellectual Property, Information Technology, Biomedical Research, and Marketing of Patented Products. <i>Handbook of Health Economics</i> , 2011, 2, 825-872.	0.2	1
263	Want More Value from Prescription Drugs? We Need to Let Prices Rise and Fall. <i>Economists' Voice</i> , 2013, 10, 39-43.	0.2	1
264	Society and the Individual at the Dawn of the Twenty-First Century. , 2016, , 41-62.		1
265	IT IS TIME FOR UNIVERSAL COVERAGE WITHOUT BREAKING THE BANK. <i>Journal of Policy Analysis and Management</i> , 2018, 37, 182-188.	1.4	1
266	Improved survival for individuals with common chronic conditions in the Medicare population. <i>Health Economics (United Kingdom)</i> , 2021, 30, 80-91.	1.7	1
267	Time to ADT and chemotherapy initiation for treatment of metastatic prostate cancer (mPC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 41-41.	1.6	1
268	Understanding the Economic Consequences of Shifting Trends in Population Health. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
269	International Differences in Longevity and Health and Their Economic Consequences. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
270	Terminal Care and the Value of Life Near its End. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1



#	ARTICLE	IF	CITATIONS
271	Want to Monitor Medicare's New Drug Benefit Program? Start by Sending a Check for \$120,000. Economists' Voice, 2008, 5, .	0.2	0
272	Market Exclusivity For Drugs: The Authors Reply. Health Affairs, 2011, 30, 799-799.	5.2	0
273	Patientsâ€™ Willingness To Pay: The Authors Reply. Health Affairs, 2012, 31, 1909-1909.	5.2	0
274	Consumer Demand and Health Effects of Cost-Sharing. , 2012, , .		0
275	Community-Acquired Pneumonia and Proton Pump Inhibitors. Journal of General Internal Medicine, 2013, 28, 874-875.	2.6	0
276	Introduction. Journal of Health Economics, 2013, 32, 1258-1262.	2.7	0
277	Health Care Costs And Clinical Outcomes Associated With Rates Of Sulfonylurea Use By Physicians. Value in Health, 2013, 16, A173-A174.	0.3	0
278	RESPONSE TO EPSTEIN'S COMMENT ON "HETEROGENEITY IN ACTION" Health Economics (United) Tj ETQq0 0,0 rgBT /Qverlock 10	1.7	0
279	The Future of US Health Care: Is Medicare Really Better at "Saving" Money?. Economists' Voice, 2014, 11, .	0.2	0
280	Hospital Productivity: The Authors Reply. Health Affairs, 2015, 34, 1069-1069.	5.2	0
281	Authorsâ€™ reply to Bosco-LÃ©vy and Salvo. BMJ, The, 2016, 354, i4330.	6.0	0
282	Are Biopharmaceutical Budget Caps Good Public Policy?. Economists' Voice, 2016, 13, 27-42.	0.2	0
283	MEDICARE"FOR"ALL: NOT OUR ONLY OPTION FOR UNIVERSAL COVERAGE. Journal of Policy Analysis and Management, 2018, 37, 195-198.	1.4	0
284	Treating people right: Who goes untreated with systemic therapy for metastatic prostate cancer (mPC)?. Journal of Clinical Oncology, 2012, 30, 125-125.	1.6	0
285	Moral Hazard and Adverse Selection in Private Health Insurance. SSRN Electronic Journal, 0, , .	0.4	0
286	Can the ACA Improve Population Health?. , 2014, , 30-38.		0
287	Valuing innovations in cancer treatment.. Journal of Clinical Oncology, 2019, 37, e18176-e18176.	1.6	0
288	347-OR: The Long-Term Effects of an Intensive Lifestyle Intervention on Medicare Outcomes. Diabetes, 2019, 68, 347-OR.	0.6	0

#	ARTICLE	IF	CITATIONS
289	The Future of the Elderly Population Health Status: Filling a Knowledge Gap. SSRN Electronic Journal, 0, , .	0.4	0
290	The Returns to Preventing Chronic Disease in Europe and the United States. Journal of Human Capital, 0, , 000-000.	1.3	0
291	Expenditures for medicaid patients treated with exenatide compared with other diabetes management regimens. American Journal of Managed Care, 2012, 18, s191-202.	1.1	0